Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements

被引:76
作者
Tan, YL
Zhou, DF
Zhang, XY
机构
[1] Yale Univ, Sch Med, Connecticut Mental Hlth Ctr, Dept Psychiat,Ribicoff Labs, New Haven, CT 06508 USA
[2] Peking Univ, Inst Mental Hlth, Beijing 100083, Peoples R China
关键词
tardive dyskinesia; brain-derived neurotrophic factor; neurotrophin; schizophrenia; symptom; sex difference;
D O I
10.1016/j.schres.2004.08.004
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Neurodegenerative processes may be involved in the pathogenesis of tardive dyskinesia (TD). Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) plays a critical role in the maintenance of functional neurons. The present study was to examine plasma BDNF levels and the relationship among BDNF level, psychopathological and tardive dyskinesia symptoms in schizophrenic patients with TD. Eighty schizophrenic patients with TD were compared with 45 schizophrenic patients without TD, as well as with 45 age-, sex-matched normal controls. The severity of TD was assessed using the Abnormal Involuntary Movement Scale (AIMS). The psychopathology of patients was assessed by the Positive and Negative Syndrome Scale (PANSS). Plasma BDNF levels were measured by sandwich enzyme-linked immunosorbent assay (ELISA). The results showed that the patients with TD had lower plasma BDNF levels than those without TD, and than that of normal controls. In the patients with TD, plasma BDNF levels was inversely correlated with AIMS total score, and with PANSS negative subscore. Female patients had significantly lower plasma BDNF levels than male TD patients. Our results suggest that decreased BDNF may play an important role in the pathophysiology of TD. There may be a relationship between decreased BDNF levels and dyskinetic movements associated with TD. (C) 2004 Elsevier B.V All rights reserved.
引用
收藏
页码:263 / 270
页数:8
相关论文
共 38 条
[21]   BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs [J].
Lipska, BK ;
Khaing, ZZ ;
Weickert, CS ;
Weinberger, DR .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 14 (01) :135-144
[22]   Oxidative mechanisms and tardive dyskinesia [J].
Lohr, JB ;
Kuczenski, R ;
Niculescu, AB .
CNS DRUGS, 2003, 17 (01) :47-62
[23]   SMOKING AND SCHIZOPHRENIA [J].
LOHR, JB ;
FLYNN, K .
SCHIZOPHRENIA RESEARCH, 1992, 8 (02) :93-102
[24]  
LOHR JB, 1991, ARCH GEN PSYCHIAT, V48, P1097
[25]  
LOHR JB, 1995, PSYCHOPHARMACOL BULL, V31, P159
[26]  
MATTSON MP, 1995, J NEUROCHEM, V65, P1740
[27]   Diagnostic and Statistical Manual of Mental Disorders [J].
Mittal, Vijay A. ;
Walker, Elaine F. .
PSYCHIATRY RESEARCH, 2011, 189 (01) :158-159
[28]   Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease [J].
Murer, MG ;
Yan, Q ;
Raisman-Vozari, R .
PROGRESS IN NEUROBIOLOGY, 2001, 63 (01) :71-124
[29]   Medial nigral dopamine neurons have rich neurotrophin support in humans [J].
Nishio, T ;
Furukawa, S ;
Akiguchi, I ;
Sunohara, N .
NEUROREPORT, 1998, 9 (12) :2847-2851
[30]   Transport of brain-derived neurotrophic factor across the blood-brain barrier [J].
Pan, WH ;
Banks, WA ;
Fasold, MB ;
Bluth, J ;
Kastin, AJ .
NEUROPHARMACOLOGY, 1998, 37 (12) :1553-1561